TVTX Q4 2020 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+9.2% YoY

Gross Profit

$49M95.9% margin

Operating Income

-$119M-232.5% margin

Net Income

-$122M-238.6% margin

EPS (Diluted)

$-2.37

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$118M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$607M

Total Liabilities

$396M

Stockholders' Equity

$211M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$47M	+9.2%
Gross Profit	$49M	$40M	+23.3%
Operating Income	-$119M	-$19M	-526.1%
Net Income	-$122M	-$30M	-301.9%

Revenue Segments

Tiopronin Products

$28M56%

Bile Acid Products

$23M44%